Q-Centrix launches Infection Control solution in preparation for the CMS 2015 Final Rule

PORTSMOUTH, N.H., Aug. 13, 2014 /PRNewswire/ -- Q-Centrix®, a leader in clinical surveillance and data abstraction solutions, released its Infection Control offering today. The new technology-enabled service aims to reduce Hospital Acquired Complications (HAC) using proprietary technology and expertise from the largest team of quality professionals in the industry.

The Q-Centrix release comes days after CMS announced its hospital inpatient prospective payments systems final rule for fiscal year 2015, and was developed in close alignment with customer community of hospitals. The updated rule indicates that hospitals with the poorest performance in reducing HACs will have their Medicare pay reduced by 1 percent and that its Value Based Purchasing formula will continue to play a large role incentivizing hospitals to reduce Hospital Acquired Conditions.

"As a large purchaser of healthcare services, the government is using reimbursement leverage to change how care is delivered.  We are making an important statement today with the release of our Infection Control solution that people and technology, in tandem, are the answer to helping our partner hospitals successfully and systematically change, in order to meet the demands of healthcare reform," explains Q-Centrix Chief Executive Officer, Milton Silva-Craig.

The new infection control solution features NHSN evaluation logic and business rules for four types of screenings: Surgical site infections (SSI), central line associated blood stream infections (CLABSI), catheter associated urinary tract infections (CAUTI), and ventilator associated pneumonia (VAP).

"This release marks a significant evolution in our technology platform," explains Brian Foy, Vice President of Product Development at Q-Centrix. "We are dedicated to innovating our technology and services to allow our partner hospitals to achieve the reimbursement they deserve while avoiding penalties they don't."

Q-Centrix aims to improve patient safety in the U.S. through the use of market-leading technology coupled with the industry's largest and broadest team of quality professionals. Conducting in excess of a million quality data abstractions annually, Q-Centrix  provides its hundreds of hospital partners core measure abstraction, registry abstraction, concurrent review, infection control, and active surveillance services.

Contact: Cathy Felts, Director of Marketing, Q-Centrix
Office: 603.294.1145 ext. 131
Cell: 312.659.8243

SOURCE Q-Centrix